Home › Overactive Bladder › NCT06953271
Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection
Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * 18 years of age or older * undergoing intradetrusor BOTOX-A injections in the office setting for overactive bladder Exclusion Criteria: * cisgender male individuals * neurogenic reasons for bladder symptoms (i.e. spinal cord injury, multiple sclerosis, etc.) * known allergy and/or contraindication to methenamine hippurate * currently already taking methenamine hippurate at the time of the procedure * taking antibiotics for any reason on the day of their BOTOX-A procedure * positive UTI at time of procedure (positive dip at time of procedure) * history of bladder cancer * history of pelvic radiation * surgically altered detrusor muscle * pre-procedural need for catheterization * diagnosis of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) * pregnant or lactating individuals
About the study
The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.
What is being tested
- Methenamine Hippurate (drug)
- Typically prescribed oral antibiotic prophylaxis (drug)
Sponsor: Women and Infants Hospital of Rhode Island · Participants: 164 · Started: Aug 1, 2025
Contact the study team
- Colin Russell, MD, MPH · Phone: 401-453-7560
- Kyle Wohlrab, MD · Phone: 401-453-7560
Official record on ClinicalTrials.gov — NCT06953271
Locations in the U.S.
| Rhode Island | Women & Infants Hospital, Providence |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.